Multiple squamous cell carcinomas following introduction of nilotinib.
作者信息
Peters P, Rabbolini D, Sinnya S, Khosrotehrani K, Wagner G
机构信息
Queensland Institute of Dermatology, Brisbane, QLD, Australia; School of Medicine, University of Queensland, Brisbane, QLD, Australia.
出版信息
Clin Exp Dermatol. 2014 Oct;39(7):791-4. doi: 10.1111/ced.12388. Epub 2014 Aug 22.
PMID:25155911
Abstract
BACKGROUND
Nilotinib is a second generation tyrosine kinase inhibitor, used in the treatment of chronic myelogenous leukaemia (CML).
METHODS
We assessed a 72-year-old woman who was treated with nilotinib for CML.
RESULTS
During the year following commencement of nilotinib, the patient developed eight squamous cell carcinomas (SCCs) on her legs.
CONCLUSIONS
Development of SCC is a previously unreported adverse reaction to nilotinib.
摘要
相似文献
1
Multiple squamous cell carcinomas following introduction of nilotinib.
Clin Exp Dermatol. 2014 Oct;39(7):791-4. doi: 10.1111/ced.12388. Epub 2014 Aug 22.
2
Eruption of squamous cell carcinomas after beginning nilotinib therapy.
Dermatol Online J. 2020 Jun 15;26(6):13030/qt35b1q4vf.
3
Development of psoriasis in a patient with chronic myelogenous leukaemia during nilotinib treatment.
Eur J Haematol. 2013 Sep;91(3):270-272. doi: 10.1111/ejh.12153. Epub 2013 Jun 28.
4
Bullous sweet syndrome in a patient with t(9;22)(q34;q11)-positive chronic myeloid leukemia treated with the tyrosine kinase inhibitor nilotinib: interphase cytogenetic detection of BCR-ABL- positive lesional cells.
Arch Dermatol. 2008 Mar;144(3):361-4. doi: 10.1001/archderm.144.3.361.
5
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
Lancet Oncol. 2011 Sep;12(9):841-51. doi: 10.1016/S1470-2045(11)70201-7. Epub 2011 Aug 17.
6
T-cell prolymphocytic leukaemia in a patient with chronic myeloid leukaemia receiving nilotinib: first documented report.
J Clin Pathol. 2019 Jul;72(7):511-512. doi: 10.1136/jclinpath-2019-205799. Epub 2019 Apr 19.
7
8
Nilotinib-induced liver injury: A case report.
Medicine (Baltimore). 2020 Sep 4;99(36):e22061. doi: 10.1097/MD.0000000000022061.
9
Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study.
Leuk Res. 2018 Apr;67:109-115. doi: 10.1016/j.leukres.2018.02.013. Epub 2018 Feb 21.
10
Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.
Clin Ther. 2008 Nov;30(11):1956-75. doi: 10.1016/j.clinthera.2008.11.014.
引用本文的文献
1
Ponatinib-induced eruptive squamous cell carcinomas.
JAAD Case Rep. 2025 May 21;62:53-55. doi: 10.1016/j.jdcr.2025.04.032. eCollection 2025 Aug.
Zotero 插件